인도의 유전자 치료 시장 규모는 2025년 6,925만 달러에서 2032년 4억 9,259만 달러에 달할 것으로 예상되며, 2025-2032년 예측 기간 동안 연평균 32.35% 성장할 것으로 예상됩니다. 바이오테크 스타트업에 대한 투자 증가, 규제 당국의 승인 및 특허 부여 증가, 유전성 질환의 위협 증가, 산학 협력 증가 등이 시장 성장을 뒷받침하고 있습니다. 유전자 치료의 인기 상승은 과거 불치병으로 여겨졌던 다양한 질병에 대한 치료법 제공에 기인한 것으로 보입니다.
국내의 다양한 유전자 치료 보급을 위한 노력도 시장 확대에 긍정적인 영향을 미치고 있으며, 2024년 2월에는 기독교 의과대학(CMC) Vellore에서 혈우병 A에 대한 첫 번째 유전자 치료 임상시험이 실시되었습니다. 진행되었습니다. 이 임상시험은 환자의 조혈모세포에 FVIII 도입 유전자를 발현시키는 새로운 기술을 적용했습니다. 생명공학청은 이 벡터가 더 많은 임상시험을 거쳐 곧 인도에서 생산될 것으로 기대하고 있습니다.
또한, 인도의 연구 활동은 다양한 유전자 치료의 가용성을 증가시킬 것으로 예상되며, 2024년 6월 Union Tribal Affairs Ministry의 직원은 지정된 부족들 사이에서 매우 유행하는 유전성 혈액 질환인 겸상 적혈구 질환에 대한 효과적인 유전자 치료법을 개발하기 위해 국가가 접근하고 있다고 발표했습니다. Lancet에 발표된 논문에 따르면 인도는 헤모글로빈 S 돌연변이 아동의 출생률이 세 번째로 높은 것으로 나타났습니다. 또한 헤모글로빈 S 대립유전자 빈도도 세계에서 가장 높습니다. 따라서 이 질병을 치료하고 관리할 수 있는 효과적인 치료법에 대한 요구가 증가하고 있습니다. 이러한 발전과 정부의 노력으로 겸상적혈구증 환자들이 효과적인 치료법을 통해 질병을 극복할 수 있을 것으로 예상됩니다.
이 보고서는 인도의 유전자 치료 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 등을 제공합니다.
India gene therapy market is projected to witness a CAGR of 32.35% during the forecast period FY2025-FY2032, growing from USD 69.25 million in FY2025 to USD 492.59 million in FY2032. The growth of the market is supported by rising investments towards biotech startups, increasing approvals and provision of patents by regulatory bodies, growing threat of genetic diseases, and increasing industry-academia collaborations. The growing popularity of gene therapy can be attributed to the provision of treatment for a broad range of previously deemed incurable diseases.
The increasing efforts to propel the availability of different gene therapies in the country also positively influence the market's expansion. In February 2024, the first human clinical trials for gene therapy for hemophilia A were conducted at Christian Medical College (CMC) Vellore. The trials included deploying a new technology for expressing FVIII transgene in the patient's hematopoietic stem cell. The Department of Biotechnology hopes the vector will proceed with further clinical trials and soon be manufactured in India.
Additionally, the country's research efforts are also expected to augment the availability of different gene therapies. In June 2024, officials of the Union Tribal Affairs Ministry announced that the country is getting closer to developing an effective gene therapy for sickle cell disease, a highly prevalent genetic blood disorder among the scheduled tribes. According to an article published in the Lancet, India has the third-highest birth rate for babies with hemoglobin S mutation. It is among the highest hemoglobin S allele frequencies across the globe. Thus, the country's need for effective therapies to treat and manage the condition is increasing. Such developments and government efforts are expected to allow the patient population living with sickle cell disease to receive effective therapeutic solutions and combat the disease.
Rising Number of Approvals Boost the Market
The rise in approvals for gene therapies from different regulatory bodies and the provision of patents are propelling the Indian gene therapy market size. In January 2024, Kolon Life Science, Inc. announced that their patent KLS-3021, recombinant vaccinia virus for anti-cancer gene therapy, and KLS-2031, treating and alleviating pain for neuropathic pain gene therapy, won registration in India. Such approvals can be attributed to the successful outcomes of different gene therapies in clinical trials and their promise of delivering more effective and targeted treatments, especially for patients with chronic and rare diseases for which effective treatment options remain unavailable. The innovative approach aids in treating various diseases by delivering functional genes in cells to replace defective or missing genes.
Additionally, due to the vast potential of gene therapy to provide a cure for a wide range of diseases and disorders, research activities to assess their functioning and evaluate their safety and efficacy are increasing, ensuring the availability of new therapies and supporting the India gene therapy market growth.
Increasing Collaborations Support Market Expansion
The increasing collaborations between leading biotech companies and research institutions in the country are expected to bolster the India gene therapy market. In July 2024, Miltenyi Biotec B.V. & Co. KG and Translational Health Science and Technology Institute (THSTI) announced a partnership for exploring gene and cell therapies for cancer treatment. Through collaboration, both organizations aim to address the increasing requirements for innovative cancer therapies and sickle cell disease. Such partnerships are expected to bolster the development and availability of novel therapeutic solutions to meet the unmet demands of patients in arenas where conventional treatment solutions have fallen short.
Due to the broader economic and societal impact of different chronic diseases that are devoid of affordable and effective treatment solutions, research activities towards gene therapies are increasing to address the underlying cause of chronic disease and halt its progression.
Increasing Investments Bolster Market Growth
The rising investments in the development and availability of gene therapies in India are expected to provide lucrative growth opportunities to the market. These therapies can potentially treat inherited disorders and often require a course for a short period or a single dose administration and address the cause of the disease, often providing a cure. Thus, various biotech startups are increasingly focusing on developing gene therapies, including CAR-T, and are receiving more investments from major healthcare and pharmaceutical companies, augmenting the growth of the India gene therapy market. The enhanced funding opportunities and strategic partnerships allow biotech startups to focus on strengthening their in-house research and development capabilities for potential gene therapies. The potential gene therapies and their affordability for patients in India are expected to significantly impact the treatment of previously incurable diseases, including lymphoma and blood cancer, among others.
Oncological Diseases Account for Major Market Share
The growing threat of cancer in the country is propelling the India gene therapy market demand. According to estimates from the National Centre for Disease Informatics and Research (NCDIR), the estimated number of new cancer cases in the country in 2022 was 1,461,427. About one in nine individuals in the country are expected to receive a diagnosis of cancer during their lifetime. This increase is augmenting the requirement for effective treatment alternatives for cancer and bolstering investments toward developing gene therapies that aid in combating oncological diseases. Gene therapy prevents cancer growth by controlling genetic mutations or altered genes. This approach is known as somatic gene therapy and uses the cells and genes of the patients. It does not impact the germ-line cells in the reproductive system, ensuring that no genetic alterations are passed on to the next generation.
Future Market Scenario (FY2025-FY2032F)
As per the India gene therapy market analysis, the market is expected to witness significant growth in the coming years due to the increasing investments in the development of gene therapies and increasing industry-academia collaborations.
The escalating cases of chronic diseases are driving the need for effective therapeutic solutions in India, creating a pressing demand for gene therapy. The estimates and projections from the National Cancer Registry Program further underline this urgency, with the incidence of cancer cases expected to surge by 12.8% in 2025 compared to 2020.
Streamlining of regulatory processes is expected to encourage industry and investigators to initiate more clinical trials for gene therapies in the country without sacrificing rigor. Additionally, the increasing awareness about the current developments in gene therapies is expected to bridge the information gap between government-sponsored organizations, patients, scientists, and clinicians and ensure the availability of effective treatments for patients with genetic disorders.
Key Players Landscape and Outlook
The increasing efforts of the market players to launch affordable and accessible gene therapies in the country in collaboration with leading research and educational institutions are bolstering the growth of the Indian gene therapy market. In April 2024, the first home-grown gene therapy was launched in India, and it is a major breakthrough in aiding the country in battling cancer. The country's first CAR-T cell therapy was developed with a collaboration between ImmunoACT, the Indian Institute of Technology, Bombay, and Tata Memorial Hospital and is expected to inspire similar industry-academia partnerships. Such collaborations are also expected to boost the availability and accessibility of different gene therapies in India and allow the country to battle prevalent diseases that lack effective treatment solutions.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.